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Background: Hypertension is one of the key factors causing cardiovascular diseases which make up the most
frequent cause of death in industrialised nations. However about 60% of hypertensive patients in Germany treated
with antihypertensives do not reach the recommended target blood pressure. The involvement of patients in
medical decision making fulfils not only an ethical imperative but, furthermore, has the potential of higher
treatment success. One concept to enhance the active role of patients is shared decision making. Until now there
exists little information on the effects of shared decision making trainings for general practitioners on patient
participation and on lowering blood pressure in hypertensive patients.
Methods/Design: In a cluster-randomised controlled trial 1800 patients receiving antihypertensives will be
screened with 24 h ambulatory blood pressure monitoring in their general practitioners’ practices. Only patients
who have not reached their blood pressure target (approximately 1200) will remain in the study (T1 – T3). General
practitioners of the intervention group will take part in a shared decision making-training after baseline assessment
(T0). General practitioners of the control group will treat their patients as usual. Primary endpoints are change of
systolic blood pressure and change of patients’ perceived participation. Secondary endpoints are changes of
diastolic blood pressure, knowledge, medical adherence and cardiovascular risk. Data analysis will be performed
with mixed effects models.
Discussion: The hypothesis underlying this study is that shared decision making, realised by a shared decision
making training for general practitioners, activates patients, facilitates patients’ empowerment and contributes to a
better hypertension control. This study is the first one that tests this hypothesis with a (cluster-) randomised trial
and a large sample size.
Trial registration: WHO International Clinical Trials: http://apps.who.int/trialsearch/Trial.aspx?TrialID=DRKS00000125
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Hypertension is one of the key factors causing cardiovas-
cular diseases [1] which make up the most frequent
cause of death in industrialised nations [2]. In spite of
the high individual and societal burden of high blood
pressure and cardiovascular disease respectively, about
60% of hypertensive patients in Germany treated with
antihypertensives do not reach a target blood pressure of
systolic / diastolic ≤ 140/90 mmHg in clinical measure-
ment [3]. At the same time, scientific development and
socio-cultural changes have initiated a change in medical
decision making from a rather paternalistic towards a
more participatory style in which both physician and pa-
tient play an active role. In Germany, patients are
entitled to get fully informed on chances and risks of
equivalent treatments [4]. In hypertension therapy, there
is a considerable number of treatment alternatives, and
patients want to be informed about options and take
part in their treatment decisions [5].
One key concept to enhance patients’ active participa-
tion in medical decisions is shared decision making
(SDM). It is characterised as an interactive process be-
tween physician and patient, acting according to the
principle of equipoise. Both parties share information
with the aim to build a consensus about the preferred
treatment and its realisation. One precondition to realise
SDM is the existence of equivalent treatment options
[6,7].
It must be assumed that patients with hypertension
who do not reach target blood pressure despite antihy-
pertensive medication are – at least in their majority –
not able to put behaviour change and / or medical ad-
herence into practice. In these cases, first of all, general
practitioners (GP) should support patients to improve
their health behaviour [8-10].
Evidence on SDM interventions showed positive
effects of SDM on patients’ participation, satisfaction
with their treatment, decisional conflict, knowledge
about the disease, adherence, and partly clinical out-
comes [11-17]. Nevertheless, study designs, intervention
programmes and measurement instruments vary consid-
erably, sample sizes are often small and results are
inconsistent.
Within the research programme “The patient as part-
ner in medical decision making”, funded from 2001 by
the German Ministry of Health, an SDM training
programme for clinicians has been developed [6] and
evaluated in various studies [14,18].
Until now there exists little information on the effects
of SDM trainings for GPs on patient participation and
clinical outcomes [19]. This holds also for blood pres-
sure level in antihypertensive treatment where only one
study (non-randomised and with a comparably small
sample size) has been conducted until now [17]. Theaim of our study is therefore to implement and evaluate
an SDM training programme for GPs within the context
of hypertension treatment in primary care.Research objectives
Our study attempts to answer the following research
questions: Does the SDM training programme for GPs
1) enhance patients’ perceived participation?
2) optimise the blood pressure values of patients?
3) enhance patients’ knowledge about hypertension?
4) improve patient adherence?Methods/Design
The Ethical Committee of the University Medical Centre
Freiburg approved this study on 26 February 2009. A
non-substantial protocol amendment was approved on 7
March 2012 by the Ethical Committee of the University
Medical Centre Freiburg.Study design
The study will be conducted as a cluster-RCT with 40
GP practices in the Suedbaden region, Germany.
Patients who receive an antihypertensive medication will
be invited to take part in the study. After a baseline data
assessment (T0), GPs will be randomised into interven-
tion group (SDM training and dissemination of printed
patient information on hypertension and antihyperten-
sive treatment) and into control group (no training,
treatment as usual). After the intervention, three follow-
up data assessments are scheduled (T1, T2 and T3; cf.
Figure 1).Study population
General practitioners
About 120 GP practices of a network of accredited gen-
eral practitioners and academic GP practices associated
with the Department of General Practice of the Univer-
sity Medical Centre Freiburg (Germany) will be
informed about the study.Patients
Each participating GP is asked to include 30 patients in
the study who are currently treated for hypertension.
These patients have to fulfil the following criteria.
Inclusion criteria: (1) Repeated prescription of antihy-
pertensive medication, (2) at least 18 years old, (3)
insured by a statutory health fund, (4) understanding of
the German language.
Exclusion criteria: Dementia, mental handicap, or
short life expectancy
Follow-up assessments  
(T1, T2, T3) 
Clinical data
Patient questionnaires (2, 5 - 9)
Prescription data 
T3 (N = 394) 
Baseline (T0)
GP practitioners (N = 40), Patients with arterial hypertension (N =1800) 
Data assessment
Clinical data, socio-demographic data,
patient questionnaires (1-6), prescription data 
Remaining in the study  
N = 1200 
hypertensive blood pressure and / or  
relevant comorbid disorder  
Intervention group
N =20 GP; N = 600 patients 
Cluster Randomisation 
Control group
N =20 GP, N = 600 patients 
Exclusion









+ Patient information 
Treatment as usual 
Follow-up assessments  
(T1, T2, T3)
Clinical data,  
Patient questionnaires (2, 5 - 9)
Prescription data 
T3 (N = 394 ) 
Figure 1 Study protocol diagram.
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To assure a random sample of the patients in each GP
practice, medical assistants of the practices (MA) will be
instructed to invite every third consecutive patient ful-
filling the inclusion criteria to take part in the study. For
all patients fulfilling the inclusion criteria and willing to
take part in the study, a baseline assessment is per-
formed. This includes ambulatory blood pressure meas-
urement (ABPM) to screen blood pressure control in all
recruited patients, further clinical data and a patient
questionnaire. Recruiting takes place over half a year.
After baseline ABPM, patients will be classified as
‘controlled’ treated if their blood pressure values are
below the thresholds for hypertension measured by
ABPM: mean values for 24 h ≤ 130/80 mmHg, ≤ 135/
85 mmHg during the day, and ≤ 120/70 mmHg at night
[1,20]. These patients with ‘controlled’ hypertension will
be excluded from the study if none of the following
comorbid disorders are diagnosed: diabetes mellitus, cor-
onary heart disease / heart attack, stroke / transient is-
chaemic attack (TIA) or peripheral arterial occlusivedisease (PAOD). Patients with ‘uncontrolled’ arterial
hypertension – i.e. one of the thresholds mentioned
above is exceeded – remain in the study. This holds as
well for enrolled patients with any of the above-
mentioned comorbid diagnoses, irrespective of their
blood pressure values.
Randomisation of the GP practices
As soon as the baseline assessment has been completed,
GP practices will be randomised into intervention and
control group. The randomisation will be performed by
lot procedure. Thus, about half of the GPs will be
assigned to the intervention and half of the GPs to the
control group.
Intervention
GPs of the intervention group will take part in an evalu-
ated SDM training [6]. The training programme will be
adapted to the requirements of hypertension treatment
in general practice. The training involves at least two of
three training sessions, with each session lasting three
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(1) Information on arterial hypertension (epidemiology,
treatment, patient adherence etc.), (2) principles of
physician-patient-communication and risk communica-
tion, (3) information on the SDM concept including the
implementation of the steps of the SDM process [7,10],
(4) integration of Motivational Interviewing to enhance
the patients’ intrinsic motivation to change health be-
haviour [8,9], (5) introduction of a decision table listing
various options to lower cardiovascular risk, and (6) use
of case vignettes for role plays simulating physician-
patient consultations.
After the SDM training, GP practices will receive
printed patient information developed by the German
College of General Practitioners and Family Physicians
(DEGAM) regarding blood pressure and the role of
physical activity, healthy nutrition, and smoking cessa-
tion. GPs will be appealed to deliver patient information
to the patients with hypertension.
GPs of the control group treat their patients as usual.
They are invited to take part in the SDM training after
the study.
Data assessment and instruments
Clinical data
(1) Systolic and diastolic office blood pressure measure-
ment in mmHg, (2) comorbidity: diabetes mellitus (and
HbA1c), coronary heart disease / heart attack, ischaemic
stroke / transient ischaemic attack or peripheral arterial
occlusive disease, (3) cholesterol: total, HDL and LDL
cholesterol, (4) 24 h ambulatory blood pressure monitor-
ing (ABPM), (5) cardiovascular 10-year-risk score calcu-
lated according to the algorithm of the cardiovascular
risk calculator arriba (http://www.arriba-hausarzt.de/
arriba/index.html).
Patient self-reporting instruments
(1) Index reflecting patients’ intention to treat hyperten-
sion [12], (2) Medication Adherence Report Scale
(MARS-D) [21], (3) helping relationship in taking medi-
cation [22], (4) Autonomy Preference Index (API) [23],
(5) Trust in Physician Scale (TPS) [24], (6) knowledge
about hypertension (8 items; developed by our research
group), (7) medical decisions which are made with the
GP during the consultation when ABPM results are
reviewed, (8) patients’ perceived participation in medical
decision making (SDM-Q-9) [25], (9) utilisation of fur-
ther health care services.
Prescription data
(1) Current medication prescription plans of the GP
practices (before each ABPM) including data on medica-
tion to lower blood pressure and cholesterol (ATC codes
C02-C04 and C07–C10), dose and number of eachentity, and time of day when a medication is taken. (2)
Data of filled prescriptions (ATC codes C02-C04 and
C07–C10). The prescription data will be used to define a
medication possession ratio (MPR) [26] for each patient
between the beginning of 2009 and the end of 2010. This
feasibility subproject will be blinded for the study arm
status of the patient.
All used scales – except knowledge questions and util-
isation of further health care services – have been vali-
dated by other authors and translated into German by a
consensus procedure. Retranslations (from German into
English) were authorised by the original author. (The
only exception is the Trust in Physician Scale because
we could not get in contact with its authors.)
Socio-demographic and other data
Besides age, gender, degree of education, employment
status and family history of cardiovascular events we ask
whether patients are living with a partner. Furthermore
height and weight as well as tobacco consumption will
be assessed.
Study endpoints
Co-primary endpoints are (1) change of patients’ per-
ceived participation (measured by SDM-Q-9) from T0 to
T1, T2 and T3, evaluated by the mean effect over the
three time points, and (2) change of systolic blood pres-
sure (mean of 24 h), measured by ABPM [27], from T1
to T2 and T3, evaluated by the mean effect over the two
follow-up time points. While the intervention may affect
perceived participation directly at the first visit after
intervention (T1), changes in blood pressure cannot be
affected before the second visit (T2).
Secondary endpoints are (1) change of diastolic blood
pressure (24 h mean), (2) change of knowledge score, (3)
change of adherence, measured by MARS-D and the
MPR, and (4) change of cardiovascular risk score (CVR),
all evaluated by the mean effect over the two and three
follow-up time points, respectively. While the interven-
tion may affect knowledge directly after T0, the other
secondary endpoints will be affected at T2 at the
earliest.
Hypotheses on predictive factors
The study should also be used to investigate whether pa-
tient characteristics like API, CVR, MARS-D, Intention-
To-Treat-Hypertension-Index, helping relationship in
taking medication and high knowledge score may pre-
dict treatment effects.
Study procedure
In all participating GP practices identical ABPM instru-
ments will be installed by supervised personnel. Medical
assistants (MAs) of GPs will be instructed about
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collection.
Patients who agree to take part in the study sign an
informed consent form. Blood pressure, gender, age and
comorbidity of patients who do not agree to take part in
the study will be anonymously assessed to account for a
possible selection bias due to the study enrolment.
Baseline assessment
The baseline assessment includes all clinical data, socio-
demographic data and prescription data. Before the
ABPM will be performed, patients complete a first ques-
tionnaire including socio-demographic data, intention-
to-treat-hypertension index [12], medication adherence
report scale (MARS-D) [21], helping relationship in tak-
ing medication [22], Autonomy Preference Index (API)
[23], Trust in Physician Scale (TPS) [24], and knowledge
about hypertension (8 items; developed by our research
group).
If the average blood pressure in the ABPM protocol
exceeds 130/80 mmHg (24 h mean) or 135/85 mmHg
(daytime mean) or 120/70 mmHg (night mean), previous
blood pressure treatment is considered as ‘uncontrolled’
[1,20,28]. These patients – as well as patients with any
of the above-mentioned comorbidities – remain in the
study. In the following visit GPs discuss with these
patients possible consequences regarding the subsequent
treatment. Immediately after this baseline consultation,
patients will receive a second questionnaire including
the above-mentioned self-reporting instruments ‘treat-
ment decision made to control hypertension’ (instru-
ment 7) and SDM-Q-9 (instrument 8).
Follow-up assessments T1, T2, and T3
The follow-up assessments take place every 6 (+ − 2)
months. In each follow-up, all clinical data and prescrip-
tion plans will be assessed. After ABPM and the follow-
ing consultation focusing blood pressure protocol,
patients are asked to complete a follow-up questionnaire
which includes MARS, TPS, knowledge about hyperten-
sion, treatment decision made to control hypertension,
SDM-Q-9, tobacco consumption, height and weight, and
utilisation of further health services.
Incentives reliant on realisation of data assessment
The GP practices or medical assistants, respectively re-
ceive a case payment of 10 € per complete dataset of
each patient in each assessment. The ABPM equipment
will be offered to the GPs after the end of the study.
Data management
All pseudonymised data of the patient questionnaires,
forms, prescription plans, ABPM protocols and filled
prescriptions will be merged into an SPSS data file. Thequality of the data entry of each assessment will be
proved by a 10% random sample check. Additionally, ex-
tensive plausibility checks are performed.
Major analyses will be conducted by the Clinical Trials
Unit at the University Medical Centre Freiburg. Statis-
tical programming will be performed with the Statistical
Analysis System (SAS) Version 9.2 or higher.
Sample size calculation
The sample size calculation resulted in about 40 prac-
tices (20 per intervention group) with a total of 1200
patients (600 per treatment group), including about 20%
drop outs on patient as well as practice level. Hence,
data on 788 patients are expected to be available for ana-
lysis (i.e. about 33 practices with 24 patients each). Stud-
ies regarding hypertension prevalence [3,29] assume that
about 1/3 of recruited patients attain blood pressure
control. Therefore 1800 patients should be involved into
the baseline data assessment. Thereof 2/3 or 1200
patients respectively will remain in the study.
Due to changes in the statistical analysis plan, a power
calculation for the new analysis strategy has been per-




The analysis of the primary endpoints ‘change of per-
ceived participation’ and ‘change of systolic blood pres-
sure will be done according to the intention-to-treat
(ITT) principle. As we have no means to define protocol
violations on the patient level and there were made no
attempts to assess compliance at the practice level, no
per-protocol analyses are planned.
Investigation of missing pattern
Prior to the analysis, the missing patterns will be
explored. Depending on the findings, strategies will be
worked out to reduce missing values. Possible strategies
are, for example, imputation or exclusion of single items
with many missing values in questionnaires.
In addition, we will analyse the missing patterns with
respect to frequency and association with patient charac-
teristics, with outcome measurements at other time
points and with treatment status. The overall aim is to
provide arguments to justify the use of a mixed model
analysis, which formally relies on the missing at random
(MAR) assumption.
Analysis of primary and secondary endpoints
For illustration of the main trends, boxplots will be used
to visualise the distribution of primary and secondary
outcome measurements at baseline and follow-up mea-
surements as well as changes from baseline. In addition,
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blood pressure are plotted for each patient separately to
explore the individual course of measurements.
The analysis of effectiveness of the intervention on the
primary endpoints ‘change of perceived participation’
and change of systolic blood pressure will be performed
with a mixed effects model of type
Yijk ¼ μþ λYijb þ ai þ βkIi þ γ ij þ δkEijk ð1Þ
where index i specifies the practice, j the patients (j =
1,. . ., no. of study patients in the corresponding practice)
and k the time point (k = 2, 3 for systolic blood pressure
and k = 1,2,3 for perceived participation). In addition, μ
is the intercept, αi the random practice effect, βk the
fixed effect of intervention at time point Tk, γij the ran-
dom patient effect, δk the fixed effect for time point Tk,
λ the fixed effect of baseline measurement Yijb (with b =
0 for perceived participation and b = 1 for systolic blood
pressure) and Eijk the error term.
This model accounts for the variation within and
between the clusters (medical practices). The effect of
intervention (β) will be tested based on the mean of esti-
mated effects over the different follow-up time points, i.e.
β ¼ 12 β2 þ β3
 
for systolic blood pressure and β ¼
1
3 β1 þ β2 þ β3
 
for perceived participation. To adjust
for multiple testing of the (co-) primary endpoints, a
Bonferroni correction of the (two-sided) significance level
α =0.05 will be applied, resulting in α* = α/2 = 0.025.
According to the EMA points to consider adjustment
for baseline covariates [30] in ‘change from baseline’ ana-
lyses, the baseline value of the respective endpoint will
be adjusted for.
The secondary endpoints will be analysed analogously
with significance level 5%. No adjustment for multiple
testing will be used.
For the endpoints systolic and diastolic blood pressure,
medication adherence report scale (MARS) and cardio-
vascular risk score (CVR) with baseline T1, a model with
baseline T0 is also considered as a sensitivity analysis.
For the primary endpoints, an additional sensitivity
analysis based on a model adjusted for the prognostic
factors practice, age, gender, baseline values of cardio-
vascular risk and comorbidity, MARS, API, intention to
treat hypertension, helping relationship in taking medi-
cation, knowledge about hypertension, TPS and an indi-
cator for treatment outside medical practice (aggregated
over the complete study period) is conducted.
As an exploratory analysis, the influence of the prog-
nostic factors mentioned above on the primary end-
points at baseline will be investigated.
No interim analysis will be performed during the
course of the study.Analysis of hypotheses on predictive factors
The hypotheses on the predictiveness of the factors API,
CVR, intention to treat hypertension, helping relation-
ship in taking medication, adherence, and knowledge
will be addressed visually by depicting the mean values
of the change in the two primary outcomes stratified by
the factors in three (API) and two groups (all other fac-
tors) based on the terciles and median, respectively. In
addition, regression models will be fitted in analogy to
the primary analyses that are assuming identical effects
at each time point, but allowing an interaction with the
factor of interest, i.e. intervention. Since the influence of
API on the change in perceived participation is expected
to be strongest for medium sized API and less pro-
nounced for small and large values [23,31], a quadratic
transformation of API and an interaction between the
intervention and this term is included in the model
when considering API. Final statements on the predic-
tiveness will be based on the significance of the
interactions.
Additional analyses
Further analyses will be performed: (1) Association of
practice characteristics with practice specific treatment
effects, (2) predictiveness of change in a) perceived par-
ticipation and b) TPS on change in systolic blood pres-
sure, (3) association between a) change in perceived
participation and change in TPS and b) change in adher-
ence and change in perceived participation and systolic
blood pressure, (4) comparison of the MPR with
patients’ self-assessed adherence (MARS).
Power calculation for the analysis of primary endpoints
For the power calculation we assume that 788 patients
are available for analysis with 24 patients per practice
(i.e. about 33 practices) according to the original sample
size calculation (see above, section ’sample size calcula-
tion’). Since Kerry and Bland [32] state that the intra-
cluster correlation in studies where the intervention is
aimed at changing the doctor’s behaviour may be larger
than in other cluster-randomised studies, we calculate
the power assuming an intra-cluster correlation (ICC) of
0.05 and 0.03 which leads to a variance inflation factor
[33] of 2.15 and 1.69, respectively. Hence, the sample
size 788 in the cluster-randomised trial would corres-
pond to a sample size of 366 and 466 patients, respect-
ively, in a study with individual randomisation.
Since knowledge on the expected effects for systolic
blood pressure and perceived participation is rare, we
base the calculation on the standardised effect size [34].
According to Machin and Campbell (2005) [35], a stan-
dardised effect size of 0.2 and 0.5 corresponds to a small
and moderate effect of the intervention, respectively.
Under the reasonable assumption of a standardised
Table 1 Power of analysis of primary endpoints under different assumptions of the intra-cluster correlation coefficient
(ICC) and the standardised effect size
Standardised effect size 0,20 0,25 0,30 0,35 0,40 0,50 0,20 0,25 0,30 0,35 0,40 0,50
ICC 0,05 0,05 0,05 0,05 0,05 0,05 0,03 0,03 0,03 0,03 0,03 0,03
Power (in %) 37,14 55,96 73,51 86,58 94,35 99,45 46,71 67,62 84,05 93,78 98,11 99,92
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ICC (0.05) and a significance level of α = 2.5% for the
test on either co-primary endpoint, i.e. a global signifi-
cance level of 5%, the power is about 74% and 87%, re-
spectively. To account for the uncertainty in both the
effect size and ICC, we use several choices of these para-
meters to get an overview of possible settings. Depend-
ing on the specific parameter setting, the power varies
between 37% and 100% as displayed in Table 1.
These calculations are based on the assumption of
only one measurement per patient during follow-up.
They can be considered as conservative for the situation
of repeated measurements at T1, T2, and T3, since this
gives additional information (s. Table 1).Ethics and data protection
A specific data protection concept will be established in
cooperation with the data protection commissioner of
the University Medical Centre Freiburg. Patient data will
be pseudonymised prior to the analyses. The data priv-
acy protection according to } 75 SGB X will be fulfilled.
All institutions cooperating in the study agree with the
data protection concept before any data transfer will be
realised.
Patients who agree to take part in the study sign an
informed consent form approved by the Ethical Commit-
tee and the data protection commissioner of the Univer-
sity Medical Centre Freiburg.
All patient questionnaires will be sealed by patients
themselves and forwarded to the responsible medical
assistant within the GP practice, and neither medical
assistants nor GPs will have an insight into question-
naires that have been completed by patients.Discussion
Cardiovascular diseases and resulting morbidity and pre-
mature death can be reduced by increasing hypertension
control. While effective medication and a broad know-
ledge about health behaviour change to lower blood
pressure exist, many patients have difficulties with medi-
cation adherence and integrating lifestyle changes into
their everyday life. The hypothesis underlying this study
is that shared decision making realised by SDM training
for practitioners activates patients, facilitates patients’
empowerment and contributes to a better hypertension
control. This study is the first one that tests thishypothesis with a (cluster-) randomised trial and a large
sample size.
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